<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BUTABARBITAL SODIUM</span><br/>(byoo-ta-bar'bi-tal)<br/><span class="topboxtradename">Barbased, </span><span class="topboxtradename"> Butalan, </span><span class="topboxtradename"> Butisol Sodium, </span><span class="topboxtradename">Sarisol No. 2<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">barbiturate</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span><br/><b>Prototype: </b>Phenobarbital<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 30 mg, 50 mg, 100 mg tablets; 30 mg/5 mL elixir</p>
<h1><a name="action">Actions</a></h1>
<p>Intermediate-acting barbiturate, similar to phenobarbital. Appears to act at thalamus level, where it interferes with transmission
         of impulses to the cerebral cortex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Preoperative sedative agent that also is an effective antianxiety agent.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypnotic in short-term treatment of simple insomnia, as sedative for relief of anxiety, and to provide sedation preoperatively.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Porphyria; uncontrolled pain; severe respiratory disease; history of addiction; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe renal or hepatic impairment; acute abdominal conditions; older adults or debilitated patients. Safe use in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Daytime Sedation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1530 mg t.i.d. or q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 7.530 mg t.i.d.<br/><br/><span class="indicationtitle">Preoperative Sedation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg 6090 min before surgery<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 26 mg/kg in 3 equally divided doses (max: 100 mg)<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Schedule slow withdrawal following long-term use to avoid precipitating withdrawal symptoms.</li>
<li>Store in tightly covered containers, preferably at 15°30° C (59°86° F), unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, <span class="speceff-common">
<b>residual sedation</b>
</span> ("hangover"), headache. <span class="typehead">GI:</span> Nausea, vomiting, constipation, diarrhea. <span class="typehead">Skin:</span> Urticaria, skin rash. <span class="typehead">Musculoskeletal:</span> Muscle or joint pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> add to CNS and respiratory depression; butabarbital increases the metabolism of <span class="classification">oral anticoagulants</span>, <span class="classification">beta blockers</span>, <span class="classification">corticosteroids</span>, <b>doxycycline,</b>
<b>griseofulvin,</b>
<b>quinidine,</b>
<span class="classification">theophyllines</span>, <span class="classification">oral contraceptives</span>, decreasing their effectiveness. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 4060 min. <span class="typehead">Peak:</span> 34 h. <span class="typehead">Duration:</span> 68 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine primarily as metabolites. <span class="typehead">Half-Life:</span> Average 100 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for adverse effects. Older adults and debilitated patients sometimes manifest excitement, confusion, or depression.
            Children also may react with paradoxical excitement. Side rails may be advisable. Report these reactions to physician.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not drink alcoholic beverages while taking this drug. Other CNS depressants may produce additive drowsiness; do not take
            without approval of physician.
         </li>
<li>
            							Note: Prolonged use is not recommended because tolerance to drug occurs in about 14 d.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>